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This review describes normal and abnormal wound healing, the latter characterized by excessive fibrosis and scarring, which for lung can
result in morbidity and sometimes mortality. The cells, the extracellular matrix (ECM) proteins, and the growth factors regulating the
synthesis, degradation, and deposition of the ECM proteins will be discussed. Therapeutics with particular emphasis given to gene
therapies and their effects on specific signaling pathways are described. Bleomycin (BM), a potent antineoplastic antibiotic increases TGF-
b1 transcription, TGF-b1 gene expression, andTGF-b protein. Like TGF-b1, BM acts through the same distal promoter cis-element of the
COL1A1 gene causing increasedCOL1 synthesis and lung fibrosis. Lung fibroblasts exist as subpopulationswith one subset predominately
responding to fibrogenic stimuli which could be a specific cell therapeutic target for the onset and development of pulmonary fibrosis.
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DOI: 10.1002/jcp.20972TGF-b1 is an importantmodulator in the acute repair phase of a
wound. It is a profibrotic factor that affects many cellular
functions, including fibroblast proliferation and chemotaxis,
stimulating the synthesis and deposition of connective tissue,
and the inhibition of connective tissue breakdown. Type I
collagen (COL 1) is the major fibrous collagen synthesized by
wound fibroblasts in the repair process.When levels of TGF-b1
are chronically elevated, excessive fibrosis results which is
characterized by increased collagen deposition. Fibrosis is the
response to a traumatic event which terminates in the
deposition of a connective tissue matrix. The composition and
volume of that matrix differentiates between normal scar in
acute wound repair and excessive fibrosis from chronic
inflammation. In general, excess fibrosis contains increased
concentrations of collagen, a rich blood supply, and
myofibroblasts, identified by a-smooth muscle (SM) actin in
cytoplasmic stress fibers. The development of fibrosis follows
the sequence of overlapping phases; lag, proliferative, and
remodeling. Either prolonging the proliferative phase and/or
hindering the remodeling phase causes excess fibrosis.
Trauma initiates the repair process that can terminate in a
normal flat scar or a raised hypertrophic scar. The acute wound
repair process provides a rapid and efficient way to restore
mechanical tissue integrity.On the other hand, excess fibrosis is
a prolonged process that can terminate into functional
morbidity. An early event in repair is the restoration of
homeostasis by the deposition of a fibrin clot which forms the
highway for the migration of cells into the defect. At the
termination of fibrosis, the fibrin matrix is replaced with a
collagen matrix. The initial cells to travel the fibrin highway are
the inflammatory cells. First, neutrophils enter the wound site
followed bymacrophages. Inflammatory cells preventmicrobial
colonization, remove dead tissue, and release factors that
promote the proliferative phase. Fibroblasts and endothelial
cells migrate into the wound site, where they synthesize and
deposit a new vascularized connective tissue matrix called
granulation tissue. In granulation tissue endothelial cells initially
form capillaries which develop into blood vessels, that is the
process of angiogenesis. Fibroblasts in granulation tissue
transform into myofibroblasts. Granulation tissue matures into 2 0 0 7 W I L E Y - L I S S , I N C .scar during the remodeling phase in which the density of
capillaries and blood vessels decline and myofibroblasts enter
apoptosis. The scar unlike granulation tissue has few fibroblasts
(nomyofibroblasts), a low density of blood vessels, and collagen
fibers arranged in random arrays. In excessive fibrosis, like
hypertrophic scar, there is a high density of fibroblasts and
myofibroblasts, a high density of blood vessels, and an
exuberant immature collagen matrix.
Active TGF-b1 is a major cytokine that stimulates the
transcription of the COL1A1 and COL1A2 genes which are
located on different chromosomes (Fig. 1). COL 1 contains two
polypeptide chains which are synthesized on ribosomes bound
to the rough endoplasmic reticulum (Fig. 1). Certain prolyl and
lysyl residues on each chain as they are being synthesized are
hydroxylated by P-4-H and lysyl hydroxylase (LH) located in the
cisternae of the RER (Fig. 1) and associated with ribosomes
synthesizing the proCOL polypeptides (Cutroneo et al., 1977).
P-4-H has also been shown to be associated with total lung
tissue polysomes (Rokowski et al., 1981). ProCOL1A1 and
proCOL1A2 of proCOL1 is in the ratio of 2 to 1 (Fig. 1). The
triple helical portion of proCOL1 will constitute the COL1
Fig. 1. Diagrammatic representation of the mechanisms of extracellular and intracellular signaling of BM and TGF-b1 on the expression of
the TGF-b1, proCOL1A1, proCOL1A2, and Smad 7 genes. This figure also demonstrates the synthesis and post translation hydroxylation
modification of proCOL1A1, proCOL1A2 polypeptides, collagen triple helix formation, and propeptide globular extension formation.
586 C U T R O N E O E T A L .molecule after the removal of the N and C termal globular
regions.
Nuclear P-4-H is a distinct enzyme from the P-4-H located
in the cisternae of the RER (Hofbauer et al., 2003; Marxsen
et al., 2004). The nuclear enzyme’s function is to hydroxylate
specific prolyl residue(s) of hypoxia inducible factor-1, to
ready this enhancer factor for ubiquinization, and subsequent
26 S proteosome degradation (Huang et al., 1998).
The synthesis of the different proCOL1 polypeptides is
controlled by two separate pathways, the TGF-b-activating
protein signaling pathway and the SMAD signaling pathway
(Fig. 1). When TGF-b1 reacts with cell membrane receptors,
the TGF-b activator protein signaling pathway is activated and
the COL1A1 gene is transcribed. The transcription of the
COL1A2 gene is via the SMAD pathway. Methods are available
for reducing fibrosis advanced by excess TGF-b1 accumulation.
Glucocorticoids diminish the synthesis of proCOL1 without
affecting the degradation of pro COL1A1 and pro COL1A2
mRNAs (Cutroneo and Sterling, 2004). Silencing the signal
pathways responsible for procollagen gene expression is
another possible method for reducing COL1 synthesis
associated with fibrosis. Cutroneo and Ehrlich [2006]
reported the use of dsdecoys containing the TGF-b element
in the phosphorothioate (PT) sense strands 50-
ATCCTGGCTGCCCACGGCCAGCCGGCC-30 where the
underlined base sequence represents the consensus TGF-b
element, as a novel nonsteroidal antifibrotic to control fibrosis.
Can dsdecoys alter the levels of proCOL1 and collagen
synthesis? The hallmark of chronic fibrosis is increased
extracellular matrix (ECM) protein synthesis by fibroticJOURNAL OF CELLULAR PHYSIOLOGY DOI 10.1002/JCPfibroblasts continually stimulated by TGF-b1. The most fibrous
collagen is COL1 which forms hypertrophic scar tissue and in
the case of vital organs such as the heart, liver, or lung, leads to
morbidity and in some patients death.
Bleomycin-induced pulmonary fibrosis
TGF-b1 the major profibrotic growth factor during
fibrogenesis is produced by fibroblasts, myofibroblasts,
recruited SM cells, and macrophages. This growth factor is
stored in platelets. Bleomycin (BM), the antineoplastic
antibiotic, treatment of lung fibroblasts results in an increased
transcription of TGF-b1, an increase of TGF-b1 gene
expression, and increased TGF-b protein (Breen et al., 1992;
Fig. 1). BMwas shown to act through the same distal cis-element
of the COL1A1 gene as TGF-b1 by intracellular and
extracellular signaling (King et al., 1994; Fig. 1). An autocrine
mechanism maintains homeostasis for fibroblasts to limit the
fibrogenic response to BM and TGF-b1 (Cutroneo, 2006);
through intracellular signaling by decreasing the Smad 3
transcription factor binding to a distinct SMAD binding element
in the proximal promoter of the Smad 7 inhibitory gene (Fig. 1).
The early increase of total lung TGF-b1 (i.e., 7 days post-
intratracheal BM) results from TGF-b1 production by alveolar
macrophages, which generate latent TGF-b1 complexed with
the glycoprotein thrombospondin (TSP-1) associated with
CD36. This associated complex is necessary for plasmin release
of active TGF-b1 (Yehualaeshet et al., 2000).
Alveolar epithelial cell (AEC) apoptosis is a prime factor in
pulmonary fibrosis. The onset of AEC apoptosis by BM requires
T H E R A P I E S R E G U L A T E G E N E E X P R E S S I O N I N L U N G F I B R O S I S 587the synthesis and binding of angiotensin II to receptor AT1. The
coadministration of the AT1 antagonist losartan with BM
intratratracheally reduced DNA fragmentation, the active
immunoreactive caspase 3, and total lung hydroxyproline
(Li et al., 2003).
The Smads are also involved in the pathogenesis of BM-induced
pulmonary fibrosis. Smad 3 deficient mice have decreased pro
COL1 gene expression and lung hydroxyproline content as
compared to wild-type mice treated with BM (Zhao et al.,
2002). Therefore, inhibitors of Smad 3may be potential therapy
for lung fibrosis and also gene therapies directed at Smad 3.
However, the SMAD signaling pathways is involved in the
regulation of many diverse gene pathways. IL-7-inhibition of the
TGF-b1 signaling pathway in lung fibroblasts results from
increased Smad 7, the major inhibitory Smad of the SMAD
signaling pathway (Huang et al., 2002). Recombinant IL-7 in vivo
decreases BM-induced pulmonary fibrosis.
P38 mitogen-activator protein kinase (MAPK), a major signal
transduction pathway of pro-inflammatory cytokines, and its
substrate activating transcription factor (ATF)-2 were found to
be phosphorylated in bronchoalveolavar fluid cells in
intratracheal BM-treated mice (Matsuoka et al., 2002). In this
study, the phosphorylation of (ATF)-2 was inhibited by the
subcutaneous injection of a specific inhibitor of thisMAP kinase.
This inhibitor also decreased the expression of tumor necrosis
factor-alpha, connective tissue growth factor (CTGF),
apoptosis of lung cells, and pulmonary fibrosis in BM-induced
lung fibrosis. Cytoplasmic phospholipase A(2) (cPLA-2), a key
enzyme in the generation of pro-inflammatory eicosanoids, is
important in the pathogenesis of murine BM-induced
pulmonary fibrosis. Mutation of the cPLA2 gene abrogated
fibrosis and inflammation in BM-induced lung fibrosis (Nagase
et al., 2002). Lung collagen deposition during pulmonary fibrosis
is a function of the ratio of tissue inhibitors of
metalloproteinases (TIMPS) and matrix metalloproteinases
(MMPs). TIMP-1 gene expression and protein are selectively
increased during murine BM-induced pulmonary fibrosis
(Madtes et al., 2001). In situ hybridization showed that the
TIMP-1 mRNA was spatially restricted to the areas of lung
injury.
TGF-b, fibrosis, and col1 synthesis
TGF-b1 is themajor profibrotic growth factorwhich stimulates
fibroblast collagen production and deposition. The three
known isoforms of TGF-b stimulate cultured fibroblast
procollagen synthesis but are differentially expressed in
BM-induced murine pulmonary fibrosis (Coker et al., 1997).
However, these studies only determined gene expression and
not protein profiles.
The SMAD signaling pathway transmits the signal from the
TGF-b receptor I on the cellular membrane to the nucleus
through the cytoplasm (for review see Heldin et al., 1997;
Fig. 1). Increased transcription of the COL1A2 gene by TGF-b1
is determined by the binding of a Smad 3/Smad 4 to the TbRE
cis-element in the proximal promoter region of this gene
(Zhang et al., 2000; Fig. 1). Sp1 also binds to this complex.
Recently, it has been shown that TGF-b cytostatic signals rely
on a Smad 3 but not a Smad 2 dependent pathway (Kim et al.,
2005). In addition, the TGF-b signaling level depends on the
Smad 3/Smad 2 ratio. A Smad 3/Smad 4 complex is required for
Smad 7 gene transcription (Fig. 1) by TGF-b1 which codes for
this major inhibitory Smad 7 (Von Gersdorff et al., 2000).
TGF-b1 induction of the COL1A2 gene depends on a 25 bp cis-
element in the proximal promoter of this gene. This is an AP-1
site and this sequence is essential for theTGF-b responsewhich
may not require Sp-1 binding sites on this gene (Chung et al.,
1996). Another study demonstrated that Sp-1 but not Ap-1 is
required for the upregulation of COL1A2 gene transcriptionJOURNAL OF CELLULAR PHYSIOLOGY DOI 10.1002/JCP(Greenwell et al., 1997). Treatment of fibroblasts with TGF-b1
or BM, the latter which acts on fibroblasts through TGF-b1,
increases collagen synthesis and the amount of TGF-b activator
protein/TGF-b element complex in gel mobility shift assays.
Glucocorticoids decrease collagen synthesis and the
transacting protein/TGF-b element complex (Fig. 1; Shukla
et al., 1999).
Gene therapy for BM-induced lung fibrosis
There exist many viral vectors coupled with certain genes
which attenuate BM-induced pulmonary fibrosis. BM-induced
murine lung receiving an intratracheal injection of a human
adenovirus vector carrying mouse Smad 7 cDNA resulted in
significant decreases of pro COL1 mRNA and lung
hydroxyproline content with no morphological evidence of
fibrosis as compared tomice given Smad 6 cDNA (Nakao et al.,
1999). A single adenovirus-decorin transgene treatment of
BM-induced murine lung, decreased the fibrotic response as
determined by lung hydroxyproline as compared to control
virus (Kolb et al., 2001). Murine BM-induced pulmonary fibrosis
was reduced after intra-venous injection of prostaglandin D2
synthetase cDNA-expressing fibroblasts (Ando et al., 2003).
This treatment decreased basic fibroblast growth factor,
CTGF, and the procollagen mRNAs. After the transfer of the
flt-1 gene in vivo into mouse skeletal muscle, this tissue served
as a biofactory for anti-vascular endothelial growth factor
(VEGF) since flt-1 is a specific receptor for VEGF and soluble
flt-1 binds to VEGF and competitively inhibits it from binding to
its receptors. This therapeutic strategy was used to attenuate
BM-induced pulmonary fibrosis (Hamada et al., 2005). When
rats were given intratracheal BM plus adenoviral vector
expressing the tissue factor pathway inhibitor (TFPI), there was
a decreased BM-induced procoagulant and thrombin
generation, inhibition of pulmonary fibrosis, and decreased
CTGF gene expression (Kijiyama et al., 2006).
The elucidation of molecular and signaling pathways in
eukaryotic cells is often achieved by targeting regulatory
element(s) found in the promoter or the enhancer region of
eukaryotic gene(s) using a double-stranded (ds)
oligodeoxynucleotide (ODN) containing a specific cis-element.
Our laboratory is focusing on dsODN decoys containing the
TGF-b element found in the distal promoter of the 50-flanking
region of the proCOL1A1 gene as a novel nonsteroidal
antifibrotic for achieving normal wound healing.
Dsdecoys have been useful in searching and unraveling
molecular mechanisms of the initiation of disease development.
The failure of a specific transcription factor to bind to the gene’s
cis-elementmay totally knock out specific gene expression.Our
dsdecoys have the ability to either silence or totally knockout
gene transcription depending upon decoy dose (Cutroneo and
Ehrlich, 2006). Knockout of specific mice genes is an in vivo
genomic method to observe the physiological, biochemical, and
the molecular effect(s) for eliminating the expression of a
specific gene(s) and how it alters physiology. However, often it
renders a lethal progeny. With SiRNA therapies a transfection
agent is required. However, no transfection agent is needed in
vivo when locally using the naked linearized PT dsdecoy
containing the TGF-b element to inhibit COL1. Therefore,
there are major advantages of using linearized PT dsoligo decoy
gene therapy for either silencing or knocking out specific gene
expression. First, the degree of silencing may be controlled by
dsdecoy dose. Secondly, our present in vivo studies
demonstrate that transfection methods were not required to
obtain biochemical effects of these PT dsdecoys (Cutroneo and
Chiu, 2000; Boros et al., 2005).
The central issue is that PT dsdecoys or other modified decoys
presently in the pipeline which are more potent, have better
delivery, and a longer duration of action could contain the
588 C U T R O N E O E T A L .consensus TGF-b element, decrease proCOL1 gene
expression, proCOL1 synthesis, and COL1 deposition during
fibrosis. The rationale is that the decoys containing the TGF-b
element or homologous cis-elements bind the transacting
protein preventing the latter from binding to the cis-element in
the 50 flanking region of the natural gene or other genes
resulting in transcription inhibition.We are focusing on aspects
involved in TGF-b1 induced fibrosis and the use of the TGF-b
element containing PT dsdecoys to control excessive COL1
synthesis and deposition resulting from persistent TGF-b1. In
our model of regulation of COL1 synthesis, these PT dsdecoys
act as promoter competitors, binding to the activator protein
(i.e., the transacting factor) both in the cytoplasm and nucleus.
The significance of our studies is that these novel natural
antifibrotics mimic the effect of glucocorticoids on COL1
synthesis during fibrosis without the unwanted side effects of
these steroids. Based on our previous studies on the molecular
mechanisms by which glucocorticoids selectively decrease
collagen synthesis, designed PT dsdecoys resistant to nuclease
action mimic the effects of gluocorticoids at the molecular,
cellular and in vivo levels of collagen synthesis (Cutroneo and
Sterling, 2004). However, the glucocorticoids significantly
inhibit noncollagen protein synthesis. Both the PT single-
stranded (ss) and the PT dsdecoys specifically decrease COL1
synthesis without inhibiting total noncollagen protein synthesis
(Cutroneo and Chiu, 2000; Cutroneo and Boros, 2002). In
future studies, we will determine if you specifically inhibit TGF-
b1-induced synthesis by using these PT dsdecoys, will this
inhibit pulmonary fibrogenesis?
Protein kinase C epsilon (PKC-e) and lung fibrosis
PKC-e signaling protein is involved in lung fibrogenesis.
Following microvascular injury in vivo chronic exposure to
thrombin results in the conversion of fibroblasts to
myofibroblasts with the activation of PKC-e being required
(Bogatkevich et al., 2001). Associated with these
myofibroblasts which resemble the phenotype of scleroderma
lung fibroblast, protein-activated receptor expression is
increased (Bogatkevich et al., 2005). Scleroderma lung tissue is
association with inflammatory and fibroproliferative foci.
Thrombin increases tenacin in lung fibroblasts which is
mediated by PKC-e. In fibrotic systemic sclerotic (SS) lung
fibroblasts, thrombin decreased PKC-e mediated tenacin
secretion (Tourkina et al., 2001). SS lung fibroblasts in culture
overexpressed collagen, containedmore activatedMEK/ERK as
compared to normal fibroblasts (Tourkina et al., 2005). This
same study demonstrated that antisense to PKC-e resulted in
concomitant decreases of collagen and PKC-e. The cis-PKC-e
element in the distal promoter of the PKC-e gene has a
sequence very homologous differing to TGF-b cis-element
found in the distal promoter of the COL1A1 gene by only two
bases (Cutroneo and Ehrlich, 2006). Will PKC-element
dsdecoys be as effective or more so in silencing or knocking out
COL1 synthesis and attenuating BM-induced pulmonary
fibrosis? Or will TGF-b element containing dsdecoys silence or
knockout PKC-epsilon synthesis?
Lung fibroblast heterogeneity
There are many cell types involved in BM-induced pulmonary
fibrosis including alveolar macrophages, type II AECs,
neutrophils, esinophils, myofibroblasts, both resident and
collagen synthesizing fibroblasts derived from bone marrow
progenitor cells (Hashimoto et al., 2004). Normal lung
fibroblasts exist as a heterogenous population of cells (Phipps,
1992) which can be separated and isolated by flow cytometry
and cell sorting based upon the presence of the
glycophosphatidylinositol-linked protein on the cell surfaceJOURNAL OF CELLULAR PHYSIOLOGY DOI 10.1002/JCPTHY-1(þ) and THY-1() lung fibroblast subpopulations
(Phipps, 1992). The subpopulationswhen treatedwith BMwere
assessed for active TGF-b1, Smad 3 phosphorylation, alpha-SM
actin, and fibronectin expression (Zhou et al., 2004). THY-1()
fibroblasts responded to BM treatment by increases in all four
parameters, while the THY-1 (þ) cells did not show any
stimulating effects. THY-1-1-C57 BL mice treated with BM
showed a greater fibrotic response both histopathologically,
greater TGF-b1 activation and collagen content (Hagood et al.,
2005). Breen et al. [1990] based on fibroblast cell surface
proCOL1or proCOL3 previously separated by flow cytometry
and cell sorting the heterogeneous population of lung
fibroblasts into subpopulations, one mainly expressing the
proCOL1A1 and the COL1A2 genes and the other population
mainly expressing the COL3A1 gene. Breen et al. [1992] later
demonstrated that the total lung fibroblast population treated
with BM before flow cytometry and cell sorting could be
separated into one population which responded to BM with
increased proCOL1A1 and proCOL1A2 mRNAs which lasted
for at least three passages (Breen et al., 1992). Would this
population of lung fibroblasts make an excellent specific cell
target for dsdecoy attenuation of BM-induced fibroblast
proCOL1 synthesis during BM-induced pulmonary fibrosis?
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